Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and β2-microglobulin in B-cell chronic lymphocytic leukemia

Stefano Molica, Domenico Levato, Nicola Cascavilla, Luciano Levato, Pellegrino Musto

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Soluble CD23 (sCD23) and beta-2 microglobulin (β2-m) are reliable prognostic parameters in B-cell chronic lymphocytic leukemia (CLL); however, their merit over well-established clinical variables such as clinical stages, bone marrow (BM) histology and lymphocyte doubling time (LDT) remains to be defined. Furthermore, information dealing with the impact on overall survival of the simultaneous increase of either β2-m or sCD23 are lacking. In this prospective study based on 106 B-cell CLL patients, we propose a combination of β2-m and sCD23 as a strong prognostic system whose statistical significance was mainly due to an excess of deaths in the subgroup displaying increased serum levels of either β2-m or sCD23. Multivariate survival analysis confirmed the important dominant role of such a finding, thus excluding features with a high degree of codependence (i.e. clinical stages, LDT) and including variables with low association (i.e. BM histology) in the final regression model. The presence of increased serum levels of β2- m/sCD23 and diffuse BM histology signified high-risk disease, whereas the absence of any adverse variable was associated with prolonged survival; in between there was a subgroup with only 1 characteristic which displayed an intermediate pattern of survival. Finally, on the basis combined increased serum levels of β2-m and sCD23, a better stratification of low- and intermediate-risk patients could be obtained, thus allowing the formulation of a clinico-biological staging for CLL.

Original languageEnglish
Pages (from-to)117-122
Number of pages6
JournalEuropean Journal of Haematology
Volume62
Issue number2
Publication statusPublished - 1999

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Histology
Bone Marrow
Survival
Serum
Lymphocytes
beta 2-Microglobulin
Survival Analysis
Multivariate Analysis
Prospective Studies

Keywords

  • β-m
  • B-cell CLL
  • Clinico-biological staging
  • Prognosis
  • sCD23

ASJC Scopus subject areas

  • Hematology

Cite this

Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and β2-microglobulin in B-cell chronic lymphocytic leukemia. / Molica, Stefano; Levato, Domenico; Cascavilla, Nicola; Levato, Luciano; Musto, Pellegrino.

In: European Journal of Haematology, Vol. 62, No. 2, 1999, p. 117-122.

Research output: Contribution to journalArticle

@article{4fcdc3babc814f478828de1cd5d4dee3,
title = "Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and β2-microglobulin in B-cell chronic lymphocytic leukemia",
abstract = "Soluble CD23 (sCD23) and beta-2 microglobulin (β2-m) are reliable prognostic parameters in B-cell chronic lymphocytic leukemia (CLL); however, their merit over well-established clinical variables such as clinical stages, bone marrow (BM) histology and lymphocyte doubling time (LDT) remains to be defined. Furthermore, information dealing with the impact on overall survival of the simultaneous increase of either β2-m or sCD23 are lacking. In this prospective study based on 106 B-cell CLL patients, we propose a combination of β2-m and sCD23 as a strong prognostic system whose statistical significance was mainly due to an excess of deaths in the subgroup displaying increased serum levels of either β2-m or sCD23. Multivariate survival analysis confirmed the important dominant role of such a finding, thus excluding features with a high degree of codependence (i.e. clinical stages, LDT) and including variables with low association (i.e. BM histology) in the final regression model. The presence of increased serum levels of β2- m/sCD23 and diffuse BM histology signified high-risk disease, whereas the absence of any adverse variable was associated with prolonged survival; in between there was a subgroup with only 1 characteristic which displayed an intermediate pattern of survival. Finally, on the basis combined increased serum levels of β2-m and sCD23, a better stratification of low- and intermediate-risk patients could be obtained, thus allowing the formulation of a clinico-biological staging for CLL.",
keywords = "β-m, B-cell CLL, Clinico-biological staging, Prognosis, sCD23",
author = "Stefano Molica and Domenico Levato and Nicola Cascavilla and Luciano Levato and Pellegrino Musto",
year = "1999",
language = "English",
volume = "62",
pages = "117--122",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and β2-microglobulin in B-cell chronic lymphocytic leukemia

AU - Molica, Stefano

AU - Levato, Domenico

AU - Cascavilla, Nicola

AU - Levato, Luciano

AU - Musto, Pellegrino

PY - 1999

Y1 - 1999

N2 - Soluble CD23 (sCD23) and beta-2 microglobulin (β2-m) are reliable prognostic parameters in B-cell chronic lymphocytic leukemia (CLL); however, their merit over well-established clinical variables such as clinical stages, bone marrow (BM) histology and lymphocyte doubling time (LDT) remains to be defined. Furthermore, information dealing with the impact on overall survival of the simultaneous increase of either β2-m or sCD23 are lacking. In this prospective study based on 106 B-cell CLL patients, we propose a combination of β2-m and sCD23 as a strong prognostic system whose statistical significance was mainly due to an excess of deaths in the subgroup displaying increased serum levels of either β2-m or sCD23. Multivariate survival analysis confirmed the important dominant role of such a finding, thus excluding features with a high degree of codependence (i.e. clinical stages, LDT) and including variables with low association (i.e. BM histology) in the final regression model. The presence of increased serum levels of β2- m/sCD23 and diffuse BM histology signified high-risk disease, whereas the absence of any adverse variable was associated with prolonged survival; in between there was a subgroup with only 1 characteristic which displayed an intermediate pattern of survival. Finally, on the basis combined increased serum levels of β2-m and sCD23, a better stratification of low- and intermediate-risk patients could be obtained, thus allowing the formulation of a clinico-biological staging for CLL.

AB - Soluble CD23 (sCD23) and beta-2 microglobulin (β2-m) are reliable prognostic parameters in B-cell chronic lymphocytic leukemia (CLL); however, their merit over well-established clinical variables such as clinical stages, bone marrow (BM) histology and lymphocyte doubling time (LDT) remains to be defined. Furthermore, information dealing with the impact on overall survival of the simultaneous increase of either β2-m or sCD23 are lacking. In this prospective study based on 106 B-cell CLL patients, we propose a combination of β2-m and sCD23 as a strong prognostic system whose statistical significance was mainly due to an excess of deaths in the subgroup displaying increased serum levels of either β2-m or sCD23. Multivariate survival analysis confirmed the important dominant role of such a finding, thus excluding features with a high degree of codependence (i.e. clinical stages, LDT) and including variables with low association (i.e. BM histology) in the final regression model. The presence of increased serum levels of β2- m/sCD23 and diffuse BM histology signified high-risk disease, whereas the absence of any adverse variable was associated with prolonged survival; in between there was a subgroup with only 1 characteristic which displayed an intermediate pattern of survival. Finally, on the basis combined increased serum levels of β2-m and sCD23, a better stratification of low- and intermediate-risk patients could be obtained, thus allowing the formulation of a clinico-biological staging for CLL.

KW - β-m

KW - B-cell CLL

KW - Clinico-biological staging

KW - Prognosis

KW - sCD23

UR - http://www.scopus.com/inward/record.url?scp=0032911377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032911377&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 117

EP - 122

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -